Status and phase
Conditions
Treatments
About
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
Full description
Part A (Dose Escalation) + Part B (Expansion Cohort) total up to 20 patients enrolled.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Jay Zhang, MD/PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal